Merck & Co., Inc. (MRK)
- Previous Close
117.23 - Open
117.27 - Bid 117.25 x 900
- Ask 116.97 x 900
- Day's Range
116.47 - 117.50 - 52 Week Range
99.14 - 134.63 - Volume
21,185,182 - Avg. Volume
9,922,806 - Market Cap (intraday)
297.004B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
21.70 - EPS (TTM)
5.40 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield 3.08 (2.63%)
- Ex-Dividend Date Sep 16, 2024
- 1y Target Est
139.94
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
View MorePerformance Overview: MRK
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
View MoreValuation Measures
Market Cap
297.00B
Enterprise Value
323.44B
Trailing P/E
21.70
Forward P/E
11.70
PEG Ratio (5yr expected)
0.08
Price/Sales (ttm)
4.78
Price/Book (mrq)
6.81
Enterprise Value/Revenue
5.18
Enterprise Value/EBITDA
15.71
Financial Highlights
Profitability and Income Statement
Profit Margin
21.99%
Return on Assets (ttm)
11.38%
Return on Equity (ttm)
33.38%
Revenue (ttm)
62.48B
Net Income Avi to Common (ttm)
13.74B
Diluted EPS (ttm)
5.40
Balance Sheet and Cash Flow
Total Cash (mrq)
11.35B
Total Debt/Equity (mrq)
86.57%
Levered Free Cash Flow (ttm)
11.79B